Alvotech
Alvotech is a global biopharmaceutical company, focused on developing biosimilar versions of leading monoclonal antibodies molecules.
Alvotech has raised €144M across 2 funding rounds from 2 investors, most recently a Debt round in Jan 2026. Based in Reykjavík, Iceland; founded 2013; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€144M
€143,668,122
Funding rounds
2
Investors
2
distinct backers
Active since
2019-01
latest 2026-01
Funding by year
EUR raised per year · 2026 YTDAlvotech — funding by year — interactive chart.
Data table
| Alvotech — funding by year | |
|---|---|
| 2018 | €44M |
| 2026 | €100M |
Signals
High confidenceRaise-next likelihood62
base rate 45% for Debt
- ▲ In typical raise window
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood10
base rate 11% (2+ rounds)
- ▲ €100M+ raised
- ▼ No recent equity round (debt-only or quiet)
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-01-02 | Debt | €100M | GoldenTree Asset Management | View deal → |
| 2019-01-01 | Other | €44M | Fuji Pharma | View deal → |
Investors
2Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Oura Health€779MFinland · Healthtech
Global coverage: FundingData